India is the fifth largest economy in the world.
COVID has now claimed over 200,000 lives on the subcontinent, and the knock-on effects are likely to be substantial.
Skyrocketing demand coupled with shortages of vital components is leading to bottlenecks in the supply chain of Pfizer’s and other mRNA vaccines.
Seniors wait after receiving a first dose of the COVID-19 vaccine at a vaccination clinic in Montréal, in March 2021.
THE CANADIAN PRESS/Paul Chiasson
Older adults are assets, but they shouldn’t be commodities.
Covid-19 vaccination strategies have been affected by supply woes.
The COVID-19 vaccination programme requires stringent data collection and transparency.
At the end of 2020, India applied to the WTO for a temporary suspension of intellectual property rights related to Covid-19.
Licensing agreements between pharmaceutical companies and the Medicines Patent Pool, in cooperation with the WHO, could accelerate access to doses for the poorest countries.
Ontario Premier Doug Ford posted a photo of himself making cheesecake on Twitter on May 14, 2020.
COVID-19 has shown us that we are not “all in this together” despite what politicians may want us to think.
It’s not a bad sign if you feel fine after your COVID-19 shot.
Luis Alvarez/DigitalVision via Getty Images
It’s normal for different people to mount stronger or weaker immune responses to a vaccine, but post-shot side effects won’t tell you which you are.
Parents may find it challenging to get their children comfortable going back out into the world.
Paul Bersebach/Orange County Register via Getty Images
As more people get vaccinated and different facets of society slowly reopen, challenges remain in the nation’s quest to get back to normal. Here are five articles that help illuminate the path.
We have two mRNA COVID-19 vaccines so far. But what else can this technology do?
Hospital staff in Lagos, Nigeria, administer the AstraZeneca vaccine.
AP Photo/Sunday Alamba
India and South Africa are pressing the World Trade Organization to waive patent rights to help ramp up vaccine production. There’s a better solution.
Generally speaking, fault can only be proven when the doctor has acted outside of the professional standard of care.
COVAX, the global vaccine distribution initiative, is well behind its goal of delivering 2 billion doses this year due to under-investment, vaccine nationalism and export restrictions.
This year is a whole new ball game for pandemic politics. For a prime minister not accustomed to pressure, Scott Morrison is proving far less equipped.
Workers pack syringes at India’s biggest syringe manufacturer. Government support has been key to developing this capacity.
Photo by Sajjad Hussain/AFP via Getty Images
African governments, firms and donor agencies should align their efforts to support the local manufacture of vaccines and other health equipment in African countries.
This week’s unwelcome medical advice about the AstraZeneca vaccine is the latest setback to the rollout and the Morrison government.
A healthcare worker administers an Oxford/AstraZeneca COVID-19 vaccine to her colleague at Mutuini Hospital in Nairobi. Kenya on March 3, 2021.
Photo by Dennis Sigwe/SOPA Images/LightRocket via Getty Images
Kenya grapples with two major challenges in the vaccination rollout: access to sufficient doses in light of the global shortage; and vaccine hesitancy.
Research shows small acts of kindness can make a big difference in classrooms.
kali9/E+ via Getty Images
‘Behavior vaccines’ – practices meant to improve safety and well-being – have been around for years. An educational psychologist says they are particularly important for schools to adopt now.
For some, a shot has been accompanied by pangs of guilt.
AP Photo/Lynne Sladky
Am I really eligible? Isn’t there someone more worthy of getting immunized before me? A bioethicist explains that such feelings of guilt are understandable. In fact, they are good for society.
Vaccine production staff demonstrate operations at a facility in Germany.
AP Photo/Michael Probst
Vaccine manufacturing is complex, with lots of potential points for errors. But it also has extensive quality control checks and approvals.
Charlie J Ercilla / Alamy Stock Photo
Good news for children and young people, bad news for Johnson & Johnson.